$Evaluating the antifracture efficacy of bisphosphonates.$

Evaluating the antifracture efficacy of bisphosphonates.

Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Pazianas, M, Epstein, S, Zaidi, M
Format:	Journal article
Język:	English
Wydane:	2009

Podobne zapisy

Antifracture agents for prostate cancer patients on androgen deprivation therapy
od: Bhupendra P Singh, i wsp.
Wydane: (2010-01-01)

The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
od: Angelo Fassio, i wsp.
Wydane: (2024-04-01)

Safety of bisphosphonates.
od: Pazianas, M, i wsp.
Wydane: (2011)

Bisphosphonates and bone quality.
od: Pazianas, M, i wsp.
Wydane: (2014)

Atrial fibrillation and bisphosphonate therapy.
od: Pazianas, M, i wsp.
Wydane: (2010)

Potential therapeutic effects of oral bisphosphonates on the intestine.
od: Pazianas, M, i wsp.
Wydane: (2011)

Safety issues with bisphosphonate therapy for osteoporosis.
od: Suresh, E, i wsp.
Wydane: (2014)

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
od: Pazianas, M
Wydane: (2013)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
od: Alexander J Rodríguez, i wsp.
Wydane: (2022-06-01)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
od: Alexander J Rodríguez, i wsp.
Wydane: (2021-07-01)

Bisphosphonates and colon cancer: reply.
od: Pazianas, M, i wsp.
Wydane: (2013)

Bisphosphonates and colon cancer: Reply
od: Pazianas, M, i wsp.
Wydane: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates.
od: Pazianas, M, i wsp.
Wydane: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates
od: Pazianas M, i wsp.
Wydane: (2013-10-01)

NE‐58025: A bisphosphonate with a low hydroxyapatite binding affinity
od: Michael Pazianas
Wydane: (2021-08-01)

Atrial fibrillation and the use of oral bisphosphonates.
od: Pazianas, M, i wsp.
Wydane: (2011)

Atrial fibrillation and the use of oral bisphosphonates
od: Michael Pazianas, i wsp.
Wydane: (2011-03-01)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
od: Pazianas, M, i wsp.
Wydane: (2010)

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.
od: Abrahamsen, B, i wsp.
Wydane: (2013)

NO ASSOCIATION BETWEEN THE USE OF ORAL BISPHOSPHONATES AND INCIDENCE OF ATRIAL FIBRILLATION
od: Pazianas, M, i wsp.
Wydane: (2010)

Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
od: Pazianas, M, i wsp.
Wydane: (2014)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
od: Pazianas, M, i wsp.
Wydane: (2008)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: Reply to Yarom and Elad
od: Pazianas, M, i wsp.
Wydane: (2008)

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
od: Pazianas, M, i wsp.
Wydane: (2007)

Impact of bisphosphonates in age-related macular degeneration: Retrospective cohort and nested case-control study
od: Garriga, C, i wsp.
Wydane: (2018)

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
od: Pazianas, M, i wsp.
Wydane: (2012)

Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
od: Pazianas, M, i wsp.
Wydane: (2013)

Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
od: Garriga, C, i wsp.
Wydane: (2018)

Impact of bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
od: Garriga, C, i wsp.
Wydane: (2018)

Bisphosphonates and Age-Related Macular Degeneration: A Propensity-Matched Cohort and Nested Case-Control Analysis
od: Garriga, C, i wsp.
Wydane: (2017)

Bisphosphonates
od: Bishop, N, i wsp.
Wydane: (2013)

Bisphosphonates
od: Fırat Öztürk
Wydane: (2009-04-01)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
od: Russell, R, i wsp.
Wydane: (2007)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
od: Russell, R, i wsp.
Wydane: (2007)

Safety and efficacy of bisphosphonates in thalassemia patients with osteopenia/osteoporosis
od: Sujata Sharma, i wsp.
Wydane: (2023-04-01)

Efficacy of Bisphosphonates for the Treatment of Osteoporosis in Patients with Multiple Sclerosis
od: İlke Coşkun Benlidayı, i wsp.
Wydane: (2015-08-01)

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
od: Russell, R, i wsp.
Wydane: (2008)

Bisphosphonates: An update
od: Nalliappan Ganapathy, i wsp.
Wydane: (2012-01-01)

Bisphosphonates 2006
od: Russell, R
Wydane: (2006)

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
od: Pazianas, M, i wsp.
Wydane: (2012)